search
Back to results

Controlling and Lowering Blood Pressure With The MOBIUSHD™ (CALM-FIM_EUR) (CALM-FIM_EUR)

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
MobiusHD
Sponsored by
Vascular Dynamics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Office cuff SBP ≥ 160 mmHg measured per protocol instructions (Appendix IV) following at least one (1) month of maximally tolerated therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic unless patient has history of intolerance, ineffectiveness or contraindications. Any combination medications will be counted per the active ingredient (for example, Zestoretic (Lisinopril +HCTZ) equals two (2) anti-hypertensive medications)

Exclusion Criteria:

  • Known or clinically suspected baroreflex failure or autonomic neuropathy

Sites / Locations

  • University of Cologne
  • Maastricht University Medical Center
  • St. Antonius Ziekenhuis
  • Erasmus Medical Center
  • HagaZiekenhuis
  • Universitair Medisch Centrum Utrecht

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

MobiusHD

Arm Description

MobiusHD

Outcomes

Primary Outcome Measures

Serious Adverse Events
Incidence of serious adverse events (SAEs) and unanticipated adverse device effects (UADE) reported for the study population from implantation through six(6) months of follow-up

Secondary Outcome Measures

Performance
Decrease in office cuff blood pressure (BP).

Full Information

First Posted
July 25, 2013
Last Updated
May 9, 2023
Sponsor
Vascular Dynamics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01911897
Brief Title
Controlling and Lowering Blood Pressure With The MOBIUSHD™ (CALM-FIM_EUR)
Acronym
CALM-FIM_EUR
Official Title
CALM-FIM_EUR - Controlling and Lowering Blood Pressure With the MobiusHD - A Prospective Multicenter Safety Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
June 2013 (Actual)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
February 28, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vascular Dynamics, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate the safety and performance of the MobiusHD system in subjects with resistant hypertension.
Detailed Description
This is an open-label, multicenter, first-in-man clinical trial to be conducted in Europe. Eligible subjects with stage 2 resistant systemic arterial hypertension currently being treated with a minimum of three (3) anti-hypertensive drugs, who consent to study participation will be assigned to treatment with the MobiusHD system. Potential study participants will be consented and then screened at two (2) baseline visits beginning at least 30 days prior to MobiusHD placement. Qualified patients will undergo placement of the MobiusHD under angiographic visualization, and will then be followed for 36 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MobiusHD
Arm Type
Experimental
Arm Description
MobiusHD
Intervention Type
Device
Intervention Name(s)
MobiusHD
Intervention Description
Implant that is placed in the carotid sinus to control hypertension.
Primary Outcome Measure Information:
Title
Serious Adverse Events
Description
Incidence of serious adverse events (SAEs) and unanticipated adverse device effects (UADE) reported for the study population from implantation through six(6) months of follow-up
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Performance
Description
Decrease in office cuff blood pressure (BP).
Time Frame
6 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Office cuff SBP ≥ 160 mmHg measured per protocol instructions (Appendix IV) following at least one (1) month of maximally tolerated therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic unless patient has history of intolerance, ineffectiveness or contraindications. Any combination medications will be counted per the active ingredient (for example, Zestoretic (Lisinopril +HCTZ) equals two (2) anti-hypertensive medications) Exclusion Criteria: Known or clinically suspected baroreflex failure or autonomic neuropathy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan Van der Heyden, MD
Organizational Affiliation
St. Antonius Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Cologne
City
Cologne
ZIP/Postal Code
50937
Country
Germany
Facility Name
Maastricht University Medical Center
City
Maastricht
State/Province
AZ
ZIP/Postal Code
6202
Country
Netherlands
Facility Name
St. Antonius Ziekenhuis
City
Nieuwegein
ZIP/Postal Code
3430 EM
Country
Netherlands
Facility Name
Erasmus Medical Center
City
Rotterdam
ZIP/Postal Code
3015
Country
Netherlands
Facility Name
HagaZiekenhuis
City
The Hague
ZIP/Postal Code
2545 CH
Country
Netherlands
Facility Name
Universitair Medisch Centrum Utrecht
City
Utrecht
ZIP/Postal Code
3508 GA
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
35144789
Citation
van Kleef MEAM, Devireddy CM, van der Heyden J, Bates MC, Bakris GL, Stone GW, Williams B, Spiering W; CALM-FIM Investigators. Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study. JACC Cardiovasc Interv. 2022 Feb 14;15(3):321-332. doi: 10.1016/j.jcin.2021.12.015.
Results Reference
derived
PubMed Identifier
28870716
Citation
Spiering W, Williams B, Van der Heyden J, van Kleef M, Lo R, Versmissen J, Moelker A, Kroon A, Reuter H, Ansel G, Stone GW, Bates M; CALM-FIM_EUR investigators. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 2017 Dec 16;390(10113):2655-2661. doi: 10.1016/S0140-6736(17)32337-1. Epub 2017 Sep 1.
Results Reference
derived
PubMed Identifier
25982654
Citation
Habib N, Mahmoodi BK, Bos WJ, Tromp SC, Suttorp MJ, Bates MC, Van der Heyden J. Initial experience with therapeutic geometric modification of the carotid bulb for true resistant hypertension. EuroIntervention. 2015 May;11(1):117-20. doi: 10.4244/EIJV11I1A20.
Results Reference
derived

Learn more about this trial

Controlling and Lowering Blood Pressure With The MOBIUSHD™ (CALM-FIM_EUR)

We'll reach out to this number within 24 hrs